STOCK TITAN

Ultragenyx to Participate in Panel at Citi’s 16th Annual BioPharma Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

On September 1, 2021, Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CEO Emil D. Kakkis will speak at Citi's 16th Annual BioPharma Healthcare Conference on September 9, 2021, at 4:10 PM ET. The panel, titled Finding a Needle in a Haystack - Drug Development Strategies for Rare Disease, focuses on innovative approaches to developing therapies for rare genetic conditions. A live and archived webcast of the presentation will be available on the company's website for 90 days.

Ultragenyx is committed to addressing unmet medical needs in rare diseases through efficient drug development.

Positive
  • None.
Negative
  • None.

NOVATO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President will participate in a panel titled Finding a Needle in a Haystack - Drug Development Strategies for Rare Disease on Thursday, September 9, 2021 at Citi’s 16th Annual BioPharma Healthcare Conference at 4:10 PM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370


FAQ

What event will Ultragenyx's CEO participate in on September 9, 2021?

Emil D. Kakkis, CEO of Ultragenyx, will participate in a panel discussion at Citi’s 16th Annual BioPharma Healthcare Conference titled 'Finding a Needle in a Haystack - Drug Development Strategies for Rare Disease.'

What is the focus of the Ultragenyx panel discussion?

The panel discussion focuses on innovative drug development strategies for rare diseases.

How can I access the Ultragenyx presentation from the conference?

The live and archived webcast of the presentation can be accessed on Ultragenyx's website for 90 days after the event.

What is Ultragenyx Pharmaceutical known for?

Ultragenyx is known for developing therapies for serious rare and ultra-rare genetic diseases.

What is the stock symbol for Ultragenyx Pharmaceutical?

The stock symbol for Ultragenyx Pharmaceutical is RARE.

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

RARE Rankings

RARE Latest News

RARE Stock Data

4.01B
88.07M
3.62%
97.49%
3.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NOVATO